Fondaparinux indications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
* in patients undergoing [[hip replacement]] surgery; | * in patients undergoing [[hip replacement]] surgery; | ||
* in patients undergoing [[knee replacement]] surgery; | * in patients undergoing [[knee replacement]] surgery; | ||
* in patients undergoing abdominal surgery who are at risk for thromboembolic complications. | * in patients undergoing [[abdominal surgery]] who are at risk for thromboembolic complications. | ||
Fondaparinux sodium (Arixtra) Injection is indicated for: | Fondaparinux sodium (Arixtra) Injection is indicated for: | ||
Revision as of 19:04, 14 February 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Fondaparinux sodium (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:
- in patients undergoing hip fracture surgery, including extended prophylaxis;
- in patients undergoing hip replacement surgery;
- in patients undergoing knee replacement surgery;
- in patients undergoing abdominal surgery who are at risk for thromboembolic complications.
Fondaparinux sodium (Arixtra) Injection is indicated for:
- the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium, and
- the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.
Adapted from the FDA Package Insert.